ClinicalTrials.gg
CompletedNCT01119222Updated Mar 7, 2011Results posted

Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers

A Phase 1 interventional study of Gabapentin and Diphenhydramine in Healthy, sponsored by Pfizer. Completed at 1 site in Belgium. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-03-07.

Sponsored by Pfizer · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

Human experimental pain models are useful in understanding the mechanisms underlying clinical pain conditions and can be used to test the analgesic efficacy of drugs used in the management of pain. Once established these models can be used as mechanism biomarkers in early development clinical studies to establish proof of mechanism for novel compounds. The cold pain model is a mechanistic pain biomarker with potential application in proof of mechanism studies. In this study we aim to set up this cold pain model at a Clinical Research Unit and demonstrate we can effectively screen subjects for this model and examine the effect of morphine, diphenhydramine, and gabapentin in the cold pain model.

Read the detailed description

Cold pain methodology development

02

Conditions studied

  • Healthy

Keywords

  • Cold pain methodology
  • Healthy male volunteers
  • gabapentin
  • Diphenhydramine
  • morphine
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male volunteers having given consent to participate in the study who have no anomalies and whose vital signs are within normal range.
  • Subject having performed the cold pain test reproducibly ie, if the area under the pain-time curve (AUC) must be within 20% during successive tests within one cold pain test screening visit and within 30% between the two cold pain test screening visits.

Exclusion criteria

Exclusion Criteria:

  • Subject who have had a serious adverse reaction or significant to any of the study drugs.
  • Subjects with a history of or evidence of any neurological condition which could affect pain sensation.
  • Subjects with an AUCcpt 0-120 sec in the cold pain test of \<1000 in any of the screening tests (excluding familiarization).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
19 participants (actual)

Study arms

  • Active comparator
    Gabapentin 1200mg

    Drug: Gabapentin

  • Active comparator
    Diphenhydramine 50 mg

    Drug: Diphenhydramine

  • Active comparator
    Morphine 10 mg

    Drug: Morphine

  • Placebo comparator
    Placebo formulations

    Drug: Placebo

Interventions

  • Capsule, single 1200mg dose

  • Tablet, single 50mg dose

  • IV, single 10mg dose

  • DrugPlacebo

    Placebo formulations (Capsule, tablet, IV to match the active treatments and to be administered in a double-dummy fashion).

06

What researchers measure

Primary outcomes

  1. Average Pain (0-120 Seconds): Cold Pain Test Visual Analog Scale (VAS)

    Area under the cold pain test Visual Analog Scale (VAS) time curve (AUCcpt 0 to 120 seconds \[sec\]) averaged over the 120 sec for each time point assessed. Participant adjusted 100 millimeter (mm) electronic VAS with range of "no pain" (0) to "maximum pain" (100) at the anchor endpoints of the scale and "moderate pain" at the midpoint. Pain reported while non-dominant hand was placed in thermostatically controlled water bath at 2±1°C for a maximum of 120 sec.

    Time frame: Pre-dose, 1, 1.5, 2, 4, and 8 hours post-dose

  2. Interpolated Average Pain (0-8 Hours)

    Interpolated average pain (0 to 8 hours): area under the curve (AUC) of average pain (0 to 120 seconds) recorded at each of the time points taken over 8 hour time period divided by 8.

    Time frame: Pre-dose to 8 hours post-dose

Secondary outcomes

  1. Number of Participants With Clinically Significant Findings in Vital Signs

    Supine blood pressure measured to nearest millimeter of mercury (mmHg), pulse rate measured with automated device or manually in the brachial/radial artery for at least 30 seconds.

    Time frame: Predose, Day 1, Day 2 each treatment period, follow-up visit (at least 7 days after last dosing)

  2. Number of Participants With Clinically Significant Abnormal Findings on Physical Examination

    Full physical examination consisting of an examination of the abdomen, cardiovascular systems, lungs, lymph nodes, mouth, musculoskeletal and neurological systems, skin, extremities, head, ears, eyes, nose, throat and thyroid gland.

    Time frame: Pre-dose and follow-up visit (at least 7 days after last dosing)

  3. Number of Participants With Abnormal Findings on Electrocardiogram (ECG)

    Standard 12-lead ECG performed after subject had rested quietly for at least 10 minutes in a supine position.

    Time frame: Pre-dose and follow-up visit (at least 7 days after last dosing)

  4. Number of Participants With Abnormal Haematology, Clinical Chemistry, Urinalysis Results

    Standard haematology, clinical chemistry, and urinalysis safety laboratory tests.

    Time frame: Pre-dose, follow-up visit (at least 7 days after last dosing)

  5. Number of Participants With Abnormal Cardiac Monitoring Results

    Continuous cardiac monitoring during intervenous (IV) infusion dosing (morphine or placebo).

    Time frame: Pre-dose through duration of IV infusion dosing

  6. Number of Participants With Abnormal Pulse Oxymetry Results

    Pulse oxymetry to monitor percentage of hemoglobin saturated with oxygen during intervenous (IV) infusion dosing (morphine or placebo).

    Time frame: Predose through duration of IV infusion dosing

07

Results

Posted Mar 7, 2011

Participant flow

Participant flow — Overall Study
MilestonePlacebo, Morphine, Diphenhydramine, GabapentinMorphine, Gabapentin, Placebo, DiphenhydramineGabapentin, Diphenhydramine, Morphine, PlaceboDiphenhydramine, Placebo, Gabapentin, Morphine
Started5554
Completed5554
Not completed0000

Outcome measures

PrimaryAverage Pain (0-120 Seconds): Cold Pain Test Visual Analog Scale (VAS)

Area under the cold pain test Visual Analog Scale (VAS) time curve (AUCcpt 0 to 120 seconds \[sec\]) averaged over the 120 sec for each time point assessed. Participant adjusted 100 millimeter (mm) electronic VAS with range of "no pain" (0) to "maximum pain" (100) at the anchor endpoints of the scale and "moderate pain" at the midpoint. Pain reported while non-dominant hand was placed in thermostatically controlled water bath at 2±1°C for a maximum of 120 sec.

Time frame:
Pre-dose, 1, 1.5, 2, 4, and 8 hours post-dose
Reported as:
Mean · mm
Average Pain (0-120 Seconds): Cold Pain Test Visual Analog Scale (VAS)
mmGabapentinMorphineDiphenhydraminePlacebo
Pre-dose45.2 ± 16.1545.5 ± 16.1045.0 ± 16.6644.9 ± 15.16
1 hour41.9 ± 16.9528.6 ± 16.8845.1 ± 17.2938.4 ± 15.69
1.5 hours39.4 ± 16.2126.1 ± 18.2842.3 ± 16.6740.2 ± 17.75
2 hours40.4 ± 17.7125.6 ± 18.4440.5 ± 17.2239.5 ± 16.86
4 hours41.9 ± 16.3734.7 ± 18.2944.2 ± 17.3544.3 ± 16.70
8 hours44.7 ± 15.0636.7 ± 17.1443.8 ± 15.0844.2 ± 14.55
Statistical analysis
  • Gabapentin vs Placebo · Mixed Models Analysis · Mean difference (final values): 0.28 · 90% CI -3.82 to 4.38
  • Morphine vs Placebo · Mixed Models Analysis · Mean difference (final values): 0.58 · 90% CI -3.53 to 4.68
  • Diphenhydramine vs Placebo · Mixed Models Analysis · Mean difference (final values): 0.11 · 90% CI -3.99 to 4.22
  • Gabapentin vs Placebo · Mixed Models Analysis · Mean difference (final values): 2.14 · 90% CI -1.15 to 5.44
  • Morphine vs Placebo · Mixed Models Analysis · Mean difference (final values): -11.18 · 90% CI -14.48 to -7.89
  • Diphenhydramine vs Placebo · Mixed Models Analysis · Mean difference (final values): 5.49 · 90% CI 2.20 to 8.78
  • Gabapentin vs Placebo · Mixed Models Analysis · Mean difference (final values): -0.73 · 90% CI -5.53 to 4.08
  • Morphine vs Placebo · Mixed Models Analysis · Mean difference (final values): -13.93 · 90% CI -18.74 to -9.13
  • Diphenhydramine vs Placebo · Mixed Models Analysis · Mean difference (final values): 2.88 · 90% CI -2.01 to 7.78
  • Gabapentin vs Placebo · Mixed Models Analysis · Mean difference (final values): 0.82 · 90% CI -5.32 to 6.96
  • Morphine vs Placebo · Mixed Models Analysis · Mean difference (final values): -13.12 · 90% CI -19.14 to -7.09
  • Diphenhydramine vs Placebo · Mixed Models Analysis · Mean difference (final values): 1.58 · 90% CI -4.45 to 7.60
  • Gabapentin vs Placebo · Mean difference (final values): -2.53 · 90% CI -7.39 to 2.32
  • Morphine vs Placebo · Mixed Models Analysis · Mean difference (final values): -9.59 · 90% CI -14.44 to -4.73
  • Diphenhydramine vs Placebo · Mixed Models Analysis · Mean difference (final values): 0.00 · 90% CI -4.85 to 4.85
  • Gabapentin vs Placebo · Mixed Models Analysis · Mean difference (final values): 0.49 · 90% CI -3.23 to 4.22
  • Morphine vs Placebo · Mixed Models Analysis · Mean difference (final values): -7.47 · 90% CI -11.19 to -3.75
  • Diphenhydramine vs Placebo · Mixed Models Analysis · Mean difference (final values): -0.27 · 90% CI -3.99 to 3.45
PrimaryInterpolated Average Pain (0-8 Hours)

Interpolated average pain (0 to 8 hours): area under the curve (AUC) of average pain (0 to 120 seconds) recorded at each of the time points taken over 8 hour time period divided by 8.

Time frame:
Pre-dose to 8 hours post-dose
Reported as:
Least squares mean · hours
Interpolated Average Pain (0-8 Hours)
hoursGabpentinMorphineDiphenhydraminePlacebo
Interpolated Average Pain (0-8 Hours)42.2 ± 3.6733.4 ± 3.6743.6 ± 3.6742.8 ± 3.67
Statistical analysis
  • Gabpentin vs Placebo · Mixed Models Analysis · Mean difference (final values): -0.60 · 90% CI -4.24 to 3.04
  • Morphine vs Placebo · Mixed Models Analysis · Mean difference (final values): -9.43 · 90% CI -13.07 to -5.79
  • Diphenhydramine vs Placebo · Mixed Models Analysis · Mean difference (final values): 0.84 · 90% CI -2.80 to 4.48
SecondaryNumber of Participants With Clinically Significant Findings in Vital Signs

Supine blood pressure measured to nearest millimeter of mercury (mmHg), pulse rate measured with automated device or manually in the brachial/radial artery for at least 30 seconds.

Time frame:
Predose, Day 1, Day 2 each treatment period, follow-up visit (at least 7 days after last dosing)
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryNumber of Participants With Clinically Significant Abnormal Findings on Physical Examination

Full physical examination consisting of an examination of the abdomen, cardiovascular systems, lungs, lymph nodes, mouth, musculoskeletal and neurological systems, skin, extremities, head, ears, eyes, nose, throat and thyroid gland.

Time frame:
Pre-dose and follow-up visit (at least 7 days after last dosing)
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryNumber of Participants With Abnormal Findings on Electrocardiogram (ECG)

Standard 12-lead ECG performed after subject had rested quietly for at least 10 minutes in a supine position.

Time frame:
Pre-dose and follow-up visit (at least 7 days after last dosing)
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryNumber of Participants With Abnormal Haematology, Clinical Chemistry, Urinalysis Results

Standard haematology, clinical chemistry, and urinalysis safety laboratory tests.

Time frame:
Pre-dose, follow-up visit (at least 7 days after last dosing)
Reported as:
Number · particpants

No measurements were reported for this outcome.

SecondaryNumber of Participants With Abnormal Cardiac Monitoring Results

Continuous cardiac monitoring during intervenous (IV) infusion dosing (morphine or placebo).

Time frame:
Pre-dose through duration of IV infusion dosing
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryNumber of Participants With Abnormal Pulse Oxymetry Results

Pulse oxymetry to monitor percentage of hemoglobin saturated with oxygen during intervenous (IV) infusion dosing (morphine or placebo).

Time frame:
Predose through duration of IV infusion dosing
Reported as:
Number · participants

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gabapentin—0/19 (0%)9/19 (47.4%)
Morphine—0/19 (0%)18/19 (94.7%)
Diphenhydramine—0/19 (0%)5/19 (26.3%)
Placebo—0/19 (0%)3/19 (15.8%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventGabapentinMorphineDiphenhydraminePlacebo
NauseaGastrointestinal disorders0/197/190/190/19
Feeling abnormalGeneral disorders2/197/190/190/19
SomnolenceNervous system disorders6/197/195/191/19
DizzinessNervous system disorders1/194/190/190/19
ParaesthesiaNervous system disorders0/194/190/190/19
Hot flushVascular disorders0/194/190/190/19
Dry mouthGastrointestinal disorders0/193/190/190/19
Chest painGeneral disorders0/193/190/190/19
VomitingGastrointestinal disorders0/192/190/190/19
FatigueGeneral disorders0/191/190/192/19

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Entire Study Population
<=18 years0
Between 18 and 65 years19
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female0
Male19
08

Study locations

1 site
  • Pfizer Investigational Site
    Bruxelles, 1070, Belgium
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2010
First posted
May 7, 2010
Start
Jul 2008
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Mar 7, 2011
Last update
Mar 7, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01119222
Lead sponsor
Pfizer
First posted
May 7, 2010
Start date
Jul 2008
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Mar 7, 2011
Last update
Mar 7, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gabapentin · Diphenhydramine · Morphine

Start the discussion